SCHEMBL2562971

SCHEMBL2562971

COC(CNC(=O)c1cc(Cl)ccc1Cl)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C19 P33261 1/20 0.55
GPR139 Q6DWJ6 1/20 0.51
LMNA P02545 2/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
PSMB11 A5LHX3 1/20 0.49
PSMA7 O14818 1/20 0.49
NFKB1 P19838 1/20 0.49
PSMB1 P20618 1/20 0.49
PSMA1 P25786 1/20 0.49
PSMA2 P25787 1/20 0.49
PSMA3 P25788 1/20 0.49
PSMA4 P25789 1/20 0.49
PDE4A P27815 1/20 0.49
PSMB8 P28062 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16348371 0.87 CDK1 (0.56) HPGDLMNAHTTP2RX7CA1
SCHEMBL31104526 0.86 P2RX7 (0.56) ALDH1A1HPGDTSHRHTTHSD17B10
SCHEMBL2563546 0.86 HPGD (0.67) ALDH1A1HPGDCYP1A2LMNATSHR
SCHEMBL11436370 0.86 FADS1 (0.48) ALDH1A1LMNAKMT2ASMN1; SMN2RECQL
SCHEMBL16433347 0.84 KLKB1 (0.46) ALDH1A1CYP1A2CYP2C19LMNAP2RX7
SCHEMBL2563185 0.82 KMT2A (0.42) ALDH1A1HPGDCYP1A2CYP2C19LMNA
SCHEMBL1645411 0.81 MEN1 (0.58) ALDH1A1CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL21581972 0.79 ALDH1A1 (0.58) ALDH1A1HPGDCYP1A2CYP3A4CYP2C19
SCHEMBL7218397 0.78 LMNA (0.67) ALDH1A1HPGDCYP1A2CYP3A4CYP2C19
SCHEMBL1116656 0.78 LMNA (0.46) ALDH1A1HPGDLMNATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399416-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-02 EP disclosed
EP-1399416-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2005-12-28 EP disclosed
US-6852882-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2005-02-08 US disclosed
US-20040157916-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-08-12 US disclosed
EP-1399416-A2 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-03-24 EP disclosed
WO-2002098901-A2 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157916-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 ALDH1A1 4302/4885HPGD 2537/4885CYP1A2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.